GlobeNewsWire · VOR · October 22, 2026

Telitacicept Demonstrates Durable Preservation of Kidney Function Through Two Years in Phase 3 TELIGAN Trial in IgA Nephropathy

Get the app for more

Explore stock news, insights and company research.